Skip to main content

Table 4 Predictors of corticosteroid administration among critically ill patients with H1N1pdm09

From: The influence of corticosteroid treatment on the outcome of influenza A(H1N1pdm09)-related critical illness

  Corticosteroid treatment
Characteristics and cointerventions Univariable analysis, OR (95 % CI) p Value Multivariable analysis, OR (95 % CI) p Value
Age (per 1-year increase) 1.01 (1.00, 1.02) 0.04 1.06 (0.99, 1.02) 0.41
Female sex 1.18 (0.86, 1.63) 0.31 1.33 (0.92, 1.92) 0.13
APACHE II score (per 1-point increase) 1.01 (0.99, 1.03) 0.21 1.01 (0.99, 1.03) 0.37
Number of comorbidities per patient (per 1 increase) 1.17 (1.09, 1.26) <0.001 1.04 (0.93, 1.15) 0.51
Pulmonary comorbidity 3.24 (2.27, 4.63) <0.001 3.82 (2.48, 5.87) <0.001
Cardiac disease 1.51 (0.96, 2.38) 0.07 1.00 (0.55, 1.81) 0.99
Immune suppressiona 3.09 (1.46, 6.54) 0.003 3.58 (1.59, 8.06) 0.002
Septic shock at admissionb 1.52 (0.93, 2.48) 0.09 2.20 (1.25, 3.88) 0.006
Bacterial coinfection at admission 0.80 (0.57, 1.13) 0.19 0.71 (0.48, 1.05) 0.09
  1. APACHE Acute Physiology and Chronic Health Evaluation, CI confidence interval, OR odds ratio
  2. aImmune suppression encompasses chemotherapy for malignancy, diagnosis of HIV/AIDS, and other immunosuppression
  3. bSeptic shock at admission, as determined by the patient’s physician